<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04999163</url>
  </required_header>
  <id_info>
    <org_study_id>PVP054</org_study_id>
    <nct_id>NCT04999163</nct_id>
  </id_info>
  <brief_title>Aortix Therapy for Perioperative Reduction of Renal Injury</brief_title>
  <acronym>A Priori</acronym>
  <official_title>Aortix Therapy for Perioperative Reduction of Renal Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Procyrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Procyrion Australia Pty Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Procyrion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, non-randomized feasibility study to evaluate the safety and&#xD;
      performance of providing support with the Aortix System to patients at heightened risk of&#xD;
      acute kidney injury (AKI) undergoing abdominal or cardiovascular surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, non-randomized feasibility study to evaluate the safety and&#xD;
      performance of providing support with the Aortix System to patients at heightened risk of&#xD;
      acute kidney injury (AKI) undergoing abdominal or cardiovascular surgery. Patients who&#xD;
      decline Aortix system implant or fail to meet anatomical requirements for Aortix implant will&#xD;
      be followed in a the non-Aortix arm. Both arms will have the same visit schedule and data&#xD;
      collection requirements with the exception of data pertaining to the Aortix system. Data will&#xD;
      be reported for both groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Enrollment to 30 days post-surgery</time_frame>
    <description>Report the rate of Occurrence of Serious Adverse Events related to the Aortix therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>baseline to 72 hours post-surgery</time_frame>
    <description>Characterize change in AKI observed pre and post-surgery using the KDIGO criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>Aortix placement to 30 days post- surgery</time_frame>
    <description>Characterize the rate of perioperative use of renal replacement therapy (RRT), ultrafiltration and/or dialysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>If discharged by day 30 post-surgery</time_frame>
    <description>Characterize the rate of 30-day post-surgery readmission due to worsening renal function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>Admission to 30 days post-surgery</time_frame>
    <description>Characterize the rate of patients remaining hospitalized 7, 14 and 30 days post-surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>Admission to 30 days post-surgery</time_frame>
    <description>Characterize the length of stay in the ICU/CCU post-surgery</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Kidney Injury</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aortix System</intervention_name>
    <description>Aortix is indicated as a partial circulatory support device to increase renal perfusion and reduce the incidence of acute kidney injury (AKI) in patients undergoing abdominal or cardiac surgeries who are at heightened risk of developing AKI.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have the following risk factor(s) for AKI prior to surgery:&#xD;
&#xD;
               1. Estimated glomerular filtration rate (eGFR) of ≥ 15 and &lt; 30 ml/min/1.73m2, OR&#xD;
&#xD;
               2. eGFR ≥ 30 and &lt; 60 ml/min/1.73m2 and ONE or more of the following:&#xD;
&#xD;
                    1. Diabetes (regardless of cause) with metabolic, renal, ophthalmic,&#xD;
                       neurologic, circulatory, or other complications&#xD;
&#xD;
                    2. Documented NYHA class III or IV heart failure within 1 year prior to&#xD;
                       enrollment&#xD;
&#xD;
                    3. Left ventricular ejection fraction &lt; 35%&#xD;
&#xD;
                    4. Hypertension with comorbid heart or kidney disease&#xD;
&#xD;
                    5. Persistent Atrial Fibrillation&#xD;
&#xD;
          2. Planned abdominal or cardiac surgical procedure (that does not use femoral artery&#xD;
             cannulation for cardiopulmonary bypass) including, but not limited to:&#xD;
&#xD;
               1. Cardiac surgery including bypass surgery, surgical valve replacement or valve&#xD;
                  repair OR&#xD;
&#xD;
               2. Abdominal surgery including gastrointestinal, liver, or pancreatic surgery&#xD;
&#xD;
          3. Age &gt;21 years, willing and able to provide written informed consent.&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. An eGFR of &lt;15 ml/min/1.73m2 at enrollment&#xD;
&#xD;
          2. Current support with a durable LVAD, intra-aortic balloon pump, extracorporeal&#xD;
             membrane oxygenation (ECMO), or percutaneous ventricular assist devices (e.g., Impella&#xD;
             or TandemHeart)&#xD;
&#xD;
          3. Patient has known hypo- or hyper-coagulable state such as disseminated intravascular&#xD;
             coagulation or heparin induced thrombocytopenia (HIT)&#xD;
&#xD;
          4. Endovascular procedure with ilio-femoral access &gt;12F within previous 30 days&#xD;
&#xD;
          5. Severe Bleeding Risk (any of the following):&#xD;
&#xD;
               1. Previous intracranial bleed such that the patient cannot safely use&#xD;
                  anticoagulation per the study requirements&#xD;
&#xD;
               2. Platelet count &lt;75,000 cells/mm3&#xD;
&#xD;
               3. Uncorrectable bleeding diathesis or coagulopathy (e.g., INR ≥ 2 not due to&#xD;
                  anticoagulation therapy&#xD;
&#xD;
          6. Current endovascular stent graft in the descending aorta or ilio-femoral vessels&#xD;
&#xD;
          7. Contraindicated Anatomy:&#xD;
&#xD;
               1. Descending aortic anatomy that would prevent safe placement of the device [&lt;18 mm&#xD;
                  or &gt;31 mm aorta diameter at deployment location (measured between the superior&#xD;
                  aspect of the T10 vertebra and superior aspect of the L1 vertebra)]&#xD;
&#xD;
               2. Ilio-femoral diameter or peripheral vascular anatomy that would preclude safe&#xD;
                  placement of a 21F (outer diameter) introducer sheath&#xD;
&#xD;
               3. Abnormalities or severe vascular disease that would preclude safe access and&#xD;
                  device delivery (e.g., aneurysm with thrombus; marked tortuosity; significant&#xD;
                  narrowing or inadequate size of the abdominal aorta, iliac, or femoral arteries;&#xD;
                  or severe calcification)&#xD;
&#xD;
               4. Known connective tissue disorder (e.g., Marfan Syndrome) or other aortopathy at&#xD;
                  risk of vascular injury&#xD;
&#xD;
          8. Known hypersensitivity or contraindication to study required medications (e.g.,&#xD;
             anticoagulation therapy) or device materials (e.g., history of severe reaction to&#xD;
             nickel or nitinol)&#xD;
&#xD;
          9. Positive pregnancy test if of childbearing potential&#xD;
&#xD;
         10. Participation in any other clinical investigation that is likely to confound study&#xD;
             results or affect the study&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Beth Neely</last_name>
    <phone>832-536-1061</phone>
    <email>Beth@procyrion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tara Burt</last_name>
    <phone>832-536-1061</phone>
    <email>Tara@procyrion.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>October 2, 2021</last_update_submitted>
  <last_update_submitted_qc>October 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

